MedTrace Logo

Magnesium Treatment in Hypoparathyroidism

NCT00824226 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2011-08-29

No results posted yet for this study

Summary

Study hypothesis: supplementary magnesium may influence the blood calcium level in treated hypoparathyroid patients. Patients will be treated with supplementary magnesium (350 mg/day) for 3 weeks. Calcium and other relevant blood parameters will be measured before the treatment, at the end of treatment and 2 weeks after stopping treatment.

Conditions

  • Hypoparathyroidism

Interventions

DIETARY_SUPPLEMENT

magnesium

magnesium 350 mg tablets once a day for 3 weeks

Sponsors & Collaborators

  • University of Tartu

    lead OTHER

Principal Investigators

  • Vallo Volke, MD, PhD · University of Tartu, Institute of Physiology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2011-08-31
Completion
2011-08-31

Countries

  • Estonia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00824226 on ClinicalTrials.gov